Kiadis Pharma’s lead investigator presents results ATIR™ clinical trial at the BMT tandem meeting

Biopharmaceutical company Kiadis Pharma focused on the development of innovative cell based therapeutics in the field of bone marrow transplantation announces today the presentation of the clinical phase I/II trial results of its lead product ATIR™ by its principal investigator Dr. Denis Claude Roy at the BMT tandem meeting held in Tampa, USA from February 11 to 15.

Dr. Denis Claude Roy’s presentation with the title: “DONOR LYMPHOCYTE INFUSIONS DEPLETED OF ALLOREACTIVE T CELLS DECREASE INFECTIONS WITHOUT CAUSING GVHD AFTER HAPLOTYPE MISMATCHED MYELOABLATIVE STEM CELL TRANSPLANTATION” is scheduled during Session C on Wednesday, February 11 from 4:45 pm to 6:15 pm. 

Dr. Denis Claude Roy, head of the Cellular Therapy Program, Hospital Maisonneuve-Rosemont, Montreal, Canada: “Our results indicate that the post-transplant infusion of ATIR™, a mismatched donor lymphocyte preparation depleted of allo-reactive T-cells, does not induce acute GVHD and suggests a clinical benefit for patients receiving a haplo-transplantation which is reflected in less life-threatening infections.”

About ATIR™

ATIR™ is a cell based product of mismatched donor lymphocytes depleted of allo-reactive T-cells.  ATIR™ is designed to prevent life-threatening acute GvHD by eliminating the immune cells from the donor graft that otherwise attack the patient’s body. Useful donor immune cells that can fight infections and remaining tumor cells are, however, spared, allowing rapid and safe donor immune reconstitution post transplantation. Acute GvHD is a major complication of allogeneic bone marrow transplantations. By preventing the occurrence of acute GvHD, ATIR™ enables the use of a mismatched donor and consequently addresses a significant limitation in bone marrow transplantations, which is the timely availability of a donor. Moreover, it could improve the general outcome of bone marrow transplants.